Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 20/20 | 0.71 |
| ▸ | EPHA2 | P29317 | 18/20 | 0.71 |
| ▸ | KDR | P35968 | 18/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.71 |
| ▸ | EGFR | P00533 | 2/20 | 0.59 |
| ▸ | FLT1 | P17948 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225748 | 0.83 | EPHA2 (1.00) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL907143 | 0.82 | EPHA2 (1.00) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL906839 | 0.81 | EPHA2 (1.00) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL1223873 | 0.81 | EPHB4 (1.00) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL906740 | 0.79 | KDR (1.00) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL12941851 | 0.78 | EPHB4 (0.65) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL14147986 | 0.78 | EPHA2 (0.70) | EPHB4EPHA2KDRERBB2 | |
| SCHEMBL907593 | 0.77 | EPHB4 (0.85) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL907101 | 0.77 | EPHB4 (1.00) | EPHB4EPHA2KDRERBB2EGFR | |
| SCHEMBL2100447 | 0.77 | KDR (0.80) | EPHB4EPHA2KDRERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280003-A2 | Process for preparing receptor-type kinase modulators | Symphony Evolution, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-2277867-A2 | Compounds, pharmaceutical compositions thereof and their use in treating cancer | Symphony Evolution, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |